LEADER 03731nam 2200745 a 450 001 9910825750503321 005 20111129080413.0 010 $a9781451124538 010 $a1451124538 010 $a9781469874821 010 $a1469874822 035 $a(CKB)3400000000000422 035 $a(EBL)2031972 035 $a(OCoLC)686682029 035 $a(SSID)ssj0000445972 035 $a(PQKBManifestationID)12158423 035 $a(PQKBTitleCode)TC0000445972 035 $a(PQKBWorkID)10491383 035 $a(PQKB)10211488 035 $a(MiAaPQ)EBC2031972 035 $a(Au-PeEL)EBL2031972 035 $a(CaPaEBR)ebr10824498 035 $a(DLC) 2010023843 035 $a(DLC)9781605474311 035 $a(EXLCZ)993400000000000422 100 $a20100607d2011 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCancer chemotherapy and biotherapy $eprinciples and practice /$f[edited by] Bruce A. Chabner, Dan L. Longo 205 $a5th ed. 210 $aPhiladelphia $cWolters Kluwer Health/Lippincott Williams & Wilkins$dc2011 215 $a1 online resource (836 p.) 300 $aDescription based upon print version of record. 311 08$a9781605474311 311 08$a1605474312 320 $aIncludes bibliographical references and index. 327 $asection I. Basic principles of cancer treatment -- section II. Cytotoxic agents -- section III. Molecularly targeted therapies -- section IV. Immunologic agents -- section V. Hormonal therapy -- section VI. Supportive care -- section VII. Survivorship. 330 $a"Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents--their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. The previous edition was one of "Doody's Core Titles 2009." This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised"--Provided by publisher. 606 $aCancer$xChemotherapy 606 $aCancer$xImmunotherapy 606 $aAntineoplastic agents 606 $aBiological response modifiers 606 $aNeoplasms$xdrug therapy 606 $aAntineoplastic Agents$xtherapeutic use 606 $aBiological Products$xtherapeutic use 615 0$aCancer$xChemotherapy. 615 0$aCancer$xImmunotherapy. 615 0$aAntineoplastic agents. 615 0$aBiological response modifiers. 615 12$aNeoplasms$xdrug therapy 615 22$aAntineoplastic Agents$xtherapeutic use 615 22$aBiological Products$xtherapeutic use 676 $a616.99/4061 701 $aChabner$b Bruce$01709370 701 $aLongo$b Dan L$g(Dan Louis),$f1949-$0327601 801 0$bDNLM/DLC 801 1$bDLC 801 2$bDLC 906 $aBOOK 912 $a9910825750503321 996 $aCancer chemotherapy and biotherapy$94099078 997 $aUNINA